NO2881536T3 - - Google Patents

Info

Publication number
NO2881536T3
NO2881536T3 NO14196403A NO14196403A NO2881536T3 NO 2881536 T3 NO2881536 T3 NO 2881536T3 NO 14196403 A NO14196403 A NO 14196403A NO 14196403 A NO14196403 A NO 14196403A NO 2881536 T3 NO2881536 T3 NO 2881536T3
Authority
NO
Norway
Application number
NO14196403A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2881536T3 publication Critical patent/NO2881536T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
NO14196403A 2012-04-06 2014-12-04 NO2881536T3 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261621461P 2012-04-06 2012-04-06

Publications (1)

Publication Number Publication Date
NO2881536T3 true NO2881536T3 (no) 2018-06-30

Family

ID=49325295

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14196403A NO2881536T3 (no) 2012-04-06 2014-12-04

Country Status (29)

Country Link
US (3) US20130273053A1 (no)
EP (2) EP3366307B1 (no)
JP (3) JP6366571B2 (no)
KR (2) KR102142508B1 (no)
CN (1) CN104661676A (no)
AU (3) AU2013267909B2 (no)
BR (1) BR112014024793A2 (no)
CA (2) CA2869326C (no)
CL (1) CL2014002694A1 (no)
CY (1) CY1120736T1 (no)
DK (2) DK3366307T3 (no)
ES (2) ES2670668T3 (no)
HK (1) HK1206996A1 (no)
HR (1) HRP20180671T1 (no)
HU (1) HUE036930T2 (no)
IL (2) IL234991B (no)
IN (1) IN2014KN02324A (no)
LT (1) LT2833907T (no)
MX (2) MX2018008658A (no)
NO (1) NO2881536T3 (no)
NZ (2) NZ781091A (no)
PL (2) PL2833907T3 (no)
PT (1) PT2833907T (no)
RS (1) RS57266B1 (no)
RU (2) RU2655299C2 (no)
SI (1) SI2833907T1 (no)
TR (1) TR201806939T4 (no)
WO (1) WO2013180834A2 (no)
ZA (1) ZA201408100B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3131223C (en) * 2011-05-04 2024-01-30 Omeros Corporation Compositions for inhibiting masp-2 dependent complement activation
CN115040653A (zh) * 2012-06-18 2022-09-13 奥默罗斯公司 抑制masp-1和/或masp-2和/或masp-3的组合物和方法
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
NZ629682A (en) * 2013-03-15 2017-03-31 Omeros Corp Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
CN117630386A (zh) * 2016-11-28 2024-03-01 中外制药株式会社 包含抗原结合结构域和运送部分的多肽
EP3606965A4 (en) * 2017-04-03 2021-01-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MASP-1 ANTIBODIES AND METHODS OF USE
JP2021525728A (ja) * 2018-05-29 2021-09-27 オメロス コーポレーション Masp−2阻害剤および使用方法
CR20220074A (es) * 2019-07-31 2022-06-03 Biocryst Pharm Inc Regímenes de dosificación para inhibidores orales del factor d del complemento
CA3159172A1 (en) 2019-12-04 2021-06-10 Michael Cicirelli Masp-2 inhibitors and methods of use
CN114295594B (zh) * 2021-12-06 2023-09-19 贵州理工学院 一种基于分子信标筛选三螺旋DNA嵌入剂的“turn on”型荧光传感器

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
EP1238066A2 (en) * 1999-12-02 2002-09-11 Jens Christian Jensenius Masp-3, a complement-fixing enzyme, and uses for it
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US7043719B2 (en) * 2001-07-23 2006-05-09 Intel Corporation Method and system for automatically prioritizing and analyzing performance data for one or more, system configurations
WO2004009664A2 (en) 2002-07-19 2004-01-29 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
AU2004216176B2 (en) * 2003-02-21 2008-04-03 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
US20070253949A1 (en) * 2004-02-03 2007-11-01 Stefan Golz Diagnostics and Therapeutics for Diseases Associated with Plasma Kallikrein (KLKB1)
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5364870B2 (ja) 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP1885047B1 (en) * 2006-07-31 2008-12-31 C.R.F. Società Consortile per Azioni Electric generator device actuated by a fluid flow
CA2685714C (en) 2007-05-31 2016-04-12 University Of Washington Inducible mutagenesis of target genes
JP2012503612A (ja) * 2008-09-26 2012-02-09 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗egfr/抗igf−1r抗体
WO2010080833A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
BRPI1010534A2 (pt) * 2009-03-05 2016-03-15 Smith & Nephew Inc sistema, método e aparelho para colocação de um fio guia no colo femoral
US20120282285A1 (en) * 2009-07-17 2012-11-08 Rigshospitalet Masp isoforms as inhibitors of complement activation
WO2011057158A1 (en) * 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
JP5937197B2 (ja) * 2011-04-08 2016-06-22 ユニバーシティー オブ レスター Masp−2依存性補体活性化に関連した状態を治療するための方法

Also Published As

Publication number Publication date
RU2018114903A (ru) 2019-03-04
NZ781091A (en) 2022-04-29
EP2833907A4 (en) 2016-03-16
LT2833907T (lt) 2018-06-11
PL2833907T3 (pl) 2018-08-31
PL3366307T3 (pl) 2022-03-07
CN104661676A (zh) 2015-05-27
MX2018008658A (es) 2021-10-19
DK2833907T3 (en) 2018-05-28
KR102142508B1 (ko) 2020-08-10
RS57266B1 (sr) 2018-08-31
AU2018200721A1 (en) 2018-02-22
US20220242972A1 (en) 2022-08-04
AU2013267909B2 (en) 2018-03-01
IL274721A (en) 2020-07-30
DK3366307T3 (da) 2021-11-01
JP6366571B2 (ja) 2018-08-01
MX357540B (es) 2018-07-13
US20130273053A1 (en) 2013-10-17
EP3366307B1 (en) 2021-07-28
AU2018200721B2 (en) 2020-03-26
CL2014002694A1 (es) 2015-08-28
AU2020204163A1 (en) 2020-07-09
NZ629675A (en) 2017-02-24
BR112014024793A2 (pt) 2019-08-27
KR20200097808A (ko) 2020-08-19
PT2833907T (pt) 2018-05-29
MX2014012045A (es) 2015-05-15
TR201806939T4 (tr) 2018-06-21
US20190382505A1 (en) 2019-12-19
HK1206996A1 (en) 2016-01-22
WO2013180834A2 (en) 2013-12-05
RU2014144621A (ru) 2016-05-27
HUE036930T2 (hu) 2018-08-28
KR20150003785A (ko) 2015-01-09
RU2655299C2 (ru) 2018-05-24
EP2833907B1 (en) 2018-02-28
ES2894944T3 (es) 2022-02-16
IN2014KN02324A (no) 2015-05-01
CA3087933A1 (en) 2013-12-05
HRP20180671T1 (hr) 2018-07-13
WO2013180834A3 (en) 2014-04-03
ES2670668T3 (es) 2018-05-31
CA2869326A1 (en) 2013-12-05
CA2869326C (en) 2021-09-21
JP2021001199A (ja) 2021-01-07
IL234991B (en) 2020-06-30
AU2013267909A1 (en) 2014-11-27
NZ727063A (en) 2021-10-29
ZA201408100B (en) 2022-05-25
JP2018162307A (ja) 2018-10-18
IL274721B (en) 2022-04-01
EP2833907A2 (en) 2015-02-11
JP2015514117A (ja) 2015-05-18
EP3366307A1 (en) 2018-08-29
CY1120736T1 (el) 2019-12-11
IL234991A0 (en) 2014-12-31
KR102318623B1 (ko) 2021-11-02
RU2018114903A3 (no) 2021-08-12
SI2833907T1 (en) 2018-07-31
JP6815355B2 (ja) 2021-01-20

Similar Documents

Publication Publication Date Title
BR112014017635A2 (no)
BR112014017614A2 (no)
BR112014017592A2 (no)
BR112014017625A2 (no)
BR112014017646A2 (no)
BR112014017659A2 (no)
BR112014017638A2 (no)
AR092201A1 (no)
BR112014017607A2 (no)
BR112013027865A2 (no)
BR112014017634A2 (no)
BR112014017609A2 (no)
BR112014017673A2 (no)
BR112014017644A2 (no)
BR112014017588A2 (no)
BR112014017647A2 (no)
BR112014013184A8 (no)
BR112014017618A2 (no)
BR112014017621A2 (no)
BR112014017630A2 (no)
BR112014017627A2 (no)
BR112014017623A2 (no)
BR112014017652A2 (no)
BR112014017641A2 (no)
BR112014017622A2 (no)